Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Pharma
Johnson & Johnson's Tecvayli struts its stuff as a monotherapy
In a multiple myeloma trial, Tecvayli cut the risk of disease progression or death by 71% over standard care in patients resistant to CD38 therapy.
Kevin Dunleavy
Jan 15, 2026 10:15am
FDA 'proactively' awards J&J a national priority review voucher
Dec 15, 2025 12:33pm
ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma
Dec 9, 2025 7:30am
ASH: Regeneron eyes simpler regimens to grow bispecifics' reach
Dec 8, 2025 8:00am
J&J, Legend pull ASH paper comparing Carvykti to rival CAR-T
Nov 12, 2025 11:36am
FDA OKs Darzalex as 1st drug for smoldering multiple myeloma
Nov 6, 2025 4:27pm
